ECSP20026986A - Composiciones de péptidos tau fosforilados y sus usos - Google Patents

Composiciones de péptidos tau fosforilados y sus usos

Info

Publication number
ECSP20026986A
ECSP20026986A ECSENADI202026986A ECDI202026986A ECSP20026986A EC SP20026986 A ECSP20026986 A EC SP20026986A EC SENADI202026986 A ECSENADI202026986 A EC SENADI202026986A EC DI202026986 A ECDI202026986 A EC DI202026986A EC SP20026986 A ECSP20026986 A EC SP20026986A
Authority
EC
Ecuador
Prior art keywords
tau peptides
compositions
phosphoriled
peptides
conjugates
Prior art date
Application number
ECSENADI202026986A
Other languages
English (en)
Inventor
Marco Donata De
Elizabeth Anne Ramsburg
Andreas Muhs
Jaap Goudsmit
Verhille Marija Vukicevic
David Hickman
Charlotte Sadaka
Anish Chakkumkal
Nicolas Piot
Bosch Maria Pihlgren
Saroj Raj Ghimire
Original Assignee
Ac Immune Sa
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa, Janssen Pharmaceuticals Inc filed Critical Ac Immune Sa
Publication of ECSP20026986A publication Critical patent/ECSP20026986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen liposomas que contienen péptidos tau, preferiblemente péptidos tau fosforilados, y conjugados que contienen péptidos tau, preferiblemente péptidos tau fosforilados, conjugados 5 a un vehículo inmunogénico. También se describen composiciones farmacéuticas y usos de los liposomas y/o conjugados para tratar o prevenir una enfermedad o trastorno neurodegenerativo, tal como la enfermedad de Alzheimer.
ECSENADI202026986A 2017-10-25 2020-05-22 Composiciones de péptidos tau fosforilados y sus usos ECSP20026986A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762577157P 2017-10-25 2017-10-25

Publications (1)

Publication Number Publication Date
ECSP20026986A true ECSP20026986A (es) 2020-06-30

Family

ID=64362628

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202026986A ECSP20026986A (es) 2017-10-25 2020-05-22 Composiciones de péptidos tau fosforilados y sus usos

Country Status (25)

Country Link
US (4) US11124552B2 (es)
EP (1) EP3700556A2 (es)
JP (3) JP7550643B2 (es)
KR (2) KR20240145065A (es)
CN (2) CN117298259A (es)
AR (1) AR113792A1 (es)
AU (2) AU2018355325B2 (es)
BR (1) BR112020008168A2 (es)
CA (2) CA3079423A1 (es)
CL (2) CL2020001070A1 (es)
CO (1) CO2020006073A2 (es)
CR (1) CR20240219A (es)
DO (1) DOP2020000135A (es)
EA (1) EA202091012A1 (es)
EC (1) ECSP20026986A (es)
IL (2) IL302108A (es)
JO (1) JOP20200103A1 (es)
MA (1) MA50465A (es)
MX (2) MX2020004338A (es)
MY (1) MY202233A (es)
PH (1) PH12020550432A1 (es)
SA (1) SA520411820B1 (es)
SG (1) SG11202003556UA (es)
TW (2) TW202333768A (es)
WO (1) WO2019084118A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
WO2020123492A1 (en) * 2018-12-10 2020-06-18 New York University Monoclonal antibodies targeting c-terminal region of phosphorylated tau
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
MX2021012994A (es) * 2019-04-24 2022-03-04 Janssen Pharmaceuticals Inc Administracion heterologa de vacunas tau.
CN114341364B (zh) * 2019-07-08 2025-07-18 阿尔兹卡生物科学公司 Tau病理靶向配体
CN114728169A (zh) * 2019-09-23 2022-07-08 麦考瑞大学 tau蛋白病的治疗
US11744874B2 (en) 2019-12-20 2023-09-05 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
CN115968291A (zh) * 2020-04-22 2023-04-14 南湖制药公司 聚乙二醇化干扰素tau及其组合物和方法
CN116472055A (zh) 2020-08-07 2023-07-21 欧萨尔普罗席纳有限公司 治疗阿尔兹海默氏病的多表位疫苗
WO2022054795A1 (ja) * 2020-09-08 2022-03-17 国立大学法人大阪大学 リン酸化タウタンパク質を標的とする免疫原性組成物
CA3192429A1 (en) * 2020-09-17 2022-03-24 Robin Barbour Alpha-synuclein vaccine for the treatment of synucleinopathies
KR20240042508A (ko) * 2021-08-12 2024-04-02 얀센 파마슈티칼즈, 인코포레이티드 지속적인 면역 반응을 유도하기 위한 인산화 타우 펩티드를 함유하는 리포솜
EP4408864A4 (en) * 2021-09-29 2025-09-03 Janssen Pharmaceuticals Inc METHOD FOR SAFE ADMINISTRATION OF A TAU PHOSPHOPEPTIDE CONJUGATE
IL314865A (en) * 2022-02-09 2024-10-01 Ac Immune Sa Anti-alpha-synuclein therapeutic vaccines
CA3261968A1 (en) * 2022-07-14 2024-01-18 Vaxxinity, Inc. IMMUNOGENEOUS TAU PEPTIDE CONSTRUCTIONS
AU2024367338A1 (en) * 2023-10-24 2026-04-30 Ac Immune Sa Method of treating preclinicial alzheimer's disease
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations
KR102988842B1 (ko) 2024-10-22 2026-07-09 주식회사 엘지에너지솔루션 리튬 이차 전지용 음극, 리튬 이차 전지, 전지 모듈 및 전지 팩

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
AU690092B2 (en) 1992-12-14 1998-04-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
EA003739B1 (ru) 1997-12-03 2003-08-28 Байоджен, Инк. Гидрофобно-модифицированные белки, способы их получения и их применение
US6314469B1 (en) 1999-02-26 2001-11-06 I-Dns.Net International Pte Ltd Multi-language domain name service
AU2001273361A1 (en) 2000-07-11 2002-01-21 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
GB0114719D0 (en) 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
AU2003203079B9 (en) 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
KR100994748B1 (ko) 2002-04-19 2010-11-17 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
WO2005058137A2 (en) 2003-12-12 2005-06-30 University Of Washington Catheterscope 3d guidance and interface system
US20050261475A1 (en) 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
WO2006121656A2 (en) 2005-05-05 2006-11-16 Merck & Co., Inc. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
WO2007068105A1 (en) 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
CA2633399C (en) 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
EP2514824A3 (en) 2006-03-03 2013-01-23 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
KR20100115340A (ko) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
US9498522B2 (en) 2008-08-07 2016-11-22 Mercia Pharma Inc. Immunotherapeutic compositions for the treatment of alzheimer'S disease
CN102365295A (zh) 2009-01-30 2012-02-29 阿德利夫股份有限公司 构象动力肽
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
MX2011009654A (es) 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
EP4218794A3 (en) 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
CN102596236B (zh) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
KR20130103662A (ko) 2010-04-19 2013-09-24 엔라이프 떼라퓨틱스, 에스.엘. 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP2632434B1 (en) * 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
CA2811188C (en) 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
WO2013058350A1 (ja) 2011-10-21 2013-04-25 三菱化学株式会社 周期表第１３族金属窒化物半導体結晶の製造方法、及び該製造方法により製造される周期表第１３族金属窒化物半導体結晶
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
US20170368167A9 (en) * 2012-08-21 2017-12-28 The Institute For Molecular Medicine Compositions and methods related to neurological disorders
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
CA2952741A1 (en) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
CA2988436A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
EP4657376A3 (en) 2015-08-14 2026-03-04 Intuitive Surgical Operations, Inc. Systems and methods of registration for image-guided surgery
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
EP3551220B1 (en) 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
TW202333768A (zh) * 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
SG11202108312PA (en) * 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
MX2021012994A (es) 2019-04-24 2022-03-04 Janssen Pharmaceuticals Inc Administracion heterologa de vacunas tau.

Also Published As

Publication number Publication date
MA50465A (fr) 2020-09-02
EP3700556A2 (en) 2020-09-02
IL273980A (en) 2020-05-31
JP7550643B2 (ja) 2024-09-13
IL273980B1 (en) 2024-10-01
CN117298259A (zh) 2023-12-29
DOP2020000135A (es) 2021-04-30
JOP20200103A1 (ar) 2020-05-06
WO2019084118A2 (en) 2019-05-02
CR20240219A (es) 2024-07-09
KR20200077543A (ko) 2020-06-30
SA520411820B1 (ar) 2024-10-14
CL2020001070A1 (es) 2020-08-28
MX2024012209A (es) 2024-11-08
TWI827557B (zh) 2024-01-01
KR102710762B1 (ko) 2024-09-25
CO2020006073A2 (es) 2020-05-29
CN111787942A (zh) 2020-10-16
TW202333768A (zh) 2023-09-01
US20210388044A1 (en) 2021-12-16
KR20240145065A (ko) 2024-10-04
AU2024259871A1 (en) 2024-11-28
PH12020550432A1 (en) 2021-04-26
CA3079423A1 (en) 2019-05-02
IL273980B2 (en) 2025-02-01
MY202233A (en) 2024-04-18
IL302108A (en) 2023-06-01
JP2021501147A (ja) 2021-01-14
CN111787942B (zh) 2024-03-29
US20190119341A1 (en) 2019-04-25
EA202091012A1 (ru) 2020-08-27
AU2018355325A1 (en) 2020-05-07
BR112020008168A2 (pt) 2020-10-27
AR113792A1 (es) 2020-06-10
CL2021000217A1 (es) 2021-07-02
CA3279357A1 (en) 2026-03-02
JP7793562B2 (ja) 2026-01-05
MX2020004338A (es) 2020-10-14
US11124552B2 (en) 2021-09-21
US20250326806A1 (en) 2025-10-23
JP2023071688A (ja) 2023-05-23
AU2018355325B2 (en) 2024-11-28
US20200376078A1 (en) 2020-12-03
SG11202003556UA (en) 2020-05-28
US11958889B2 (en) 2024-04-16
WO2019084118A3 (en) 2019-06-06
JP2025163031A (ja) 2025-10-28
TW201932138A (zh) 2019-08-16

Similar Documents

Publication Publication Date Title
DOP2020000135A (es) Composiciones de péptidos tau fosforilados y sus usos
MX2025007999A (es) Conjugados de interleucina-2 (il-2)
CL2021000405A1 (es) Moduladores de calpaínas y usos terapeuticos de los mismos (divisional sol. 201900793)
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
MX2021005134A (es) Nuevos conjugados citostaticos con ligandos de integrina.
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
CL2019000115A1 (es) Compuestos y métodos para la modulación de smn2.
CL2019002240A1 (es) Dendrímeros terapéuticos.
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
MX2017007169A (es) Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
CR20170344A (es) Anticuerpos para tau y usos de los mismos
MX2016010053A (es) Composiciones de compuestos y usos de los mismos.
MX391221B (es) Compuestos y composiciones y usos de los mismos.
CU20210077A7 (es) Extractos bacterianos estables como fármacos
CY1121187T1 (el) Ενα εκχυλισμα απο indigo naturalis και μια διεργασια για την παρασκευη εκεινου
CL2019001891A1 (es) Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas.
MX2021012994A (es) Administracion heterologa de vacunas tau.
PE20151603A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos
MX2017011500A (es) Combinaciones y formulaciones de dosis fijas que comprenden ácido 8-hidroxi-2,2,14,14- tetrametilpentadecanodioico (etc1002) y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CL2017002299A1 (es) Combinaciones de dosis fija y formulaciones comprendiendo etc-1002 y ezetimiba y métodos para tratar o reducir el riesgo de enfermedades cardiovasculares
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
BR112022000297A2 (pt) Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos